1,6-naphthyridinone derivatives having angiotension II antagonist activity
AssigneeImperial Chemical Industries PLC
InventorsArnold H. Ratcliffe, Robert J. Pearce, Keith H. Gibson, Robin Wood, Brian B. Masek
Life of this patent
Estimating the term…
Abstract
The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, Ra, Rb, A, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
Claims10
A heterocyclic derivative of the formula I
- wherein R.sup.1 is hydrogen, (1-8C)alkyl, (3-8C)cycloalkyl, phenyl or substituted (1-4C)alkyl, the latter containing one or more fluoro substituents or bearing a (3-8C)cycloalkyl, (1-4C)alkoxy or phenyl substituent;
- R.sup.2 is hydrogen, (1-4C)alkyl, (1-4C)alkoxy, halogeno, trifluoromethyl, carboxy, (1-4C)alkoxycarbonyl, (3-6C)alkenyloxycarbonyl, cyano, nitro, carbamoyl, (1-4C)alkanoyl, N-alkylcarbamoyl and di-(N-alkyl)carbamoyl of up to 7 carbon atoms, amino, alkylamino and dialkylamino of up to 6 carbon atoms, 3-(1-4C)alkylureido and (1-4C)alkanoylamino;
- R.sup.3 is selected from halogeno, (1-4C)alkoxy, hydroxy, amino, alkylamino and dialkylamino of up to 6 carbon atoms, and any of the values defined for R.sup.1 ;
- A is a linking group of the formula --CH.dbd.CH--CO--, --CO--CH.dbd.CH--, --CO--CH.sub.2 --CH.sub.2 -- or --CH.sub.2 --CH.sub.2 --CO--;
- each of Ra and Rb is independently an indicated hydrogen or an optional substituent on linking group A independently selected from (1-4C)alkyl, substituted (1-4C)alkyl containing one or more fluoro substituents or bearing a (3-8C)cycloalkyl, (1-4C)alkoxy or phenyl substituent, (3-8C)cycloalkyl, phenyl, pyridyl, (1-4C)alkoxy, halogeno, carboxy, (1-4C)alkoxycarbonyl, (3-6C)alkenyloxycarbonyl, carbamoyl, N-alkylcarbamoyl and di-(N-alkyl)carbamoyl of up to 7 carbon atoms, cyano, nitro, (1-4C)alkanoyl, (1-4C)alkylthio, (1-4C)alkylsulphinyl, (1-4C)alkylsulphonyl, phenylthio, phenylsulphinyl or phenylsulphonyl;
- R.sup.4 is selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxy, halogeno, trifluoromethyl, cyano and nitro;
- X is a direct bond between the adjacent phenyl and methylene groups;
- Z is 1H-tetrazol-5-yl, --CO.NH.(1H-tetrazol-5-yl), --NHSO.sub.2 CF.sub.3 or a group of the formula --CO.OR.sup.5, --CO.NH.SO.sub.2.R.sup.6 or --SO.sub.2.NHR.sup.7 in which R.sup.5 is hydrogen or a non-toxic, biodegradable residue of a physiologically acceptable alcohol or phenol, R.sup.6 is (1-6C)alkyl, (3-8C)cycloalkyl or phenyl, and R.sup.7 is hydrogen, (1-4C)alkyl, (1-4C)alkanoyl or --CO.NH.(1-4C)alkyl;
- or Z is a 2-carboxybenzamido, 2-sulfobenzamido or 2-carboxybenzyloxy group, the benzene ring of which last three groups may optionally bear 1 or 2 additional substituents independently selected from (1-4C)alkyl, (1-4C)alkoxy and halogeno;
- and wherein any of said phenyl moieties may be unsubstituted or bear one or two substituents independently selected from (1-4C)alkyl, (1-4C)alkoxy, halogeno, cyano and trifluoromethyl;
- or an N-oxide thereof;
- or a non-toxic salt thereof.
Dependencies are inferred from the claim text.